Objective: This study addresses the effects of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) on cell death in human chondrocytes Methods: Osteoarthritis (OA) human chondrocytes stimulated with Actinomycin-D (ActD) were used as a cellular apoptotic model. Caspase family mRNA expression and protein synthesis were analyzed by the ribonuclease protection assay and Western-blot, respectively. Cell viability and apoptosis were evaluated using the 3-[4,5-dimethylthiazol-2yl] 2,5-diphenyl tetrazolium bromide (MTT) assay and flow cytometry, respectively. Prostaglandin E-2 (PGE(2)) and nitric oxide (NO) were evaluated by enzyme-linked immunosorbent assay (ELISA) and the Griess method, respectively. Results: TNF-alpha and IL-1 beta differentially affected the pattern of caspase mRNA expression by human chondrocytes. TNF-alpha induced a gradual increase in caspase-1 and -8 mRNA levels that was not seen with IL-1 beta. The time sequence of caspase-3 and -7 inductions by TNF-a differs from that induced by IL-1 beta. Cell viability was not modified by TNF-alpha or IL-1 beta in cultured chondrocytes. Then, we employed ActD as a model to facilitate cell death. Treatment with TNF-alpha, and ActD (TNF-alpha/ActD) increased cell death induced by ActD (23%). Treatment with IL-1 beta and ActD (IL-1 beta/ActD) did not modulate ActD-incluced cell death. Similarly, IL-1 beta/ActD did not induce an increase in the activation of caspase-3 and -7 and poly (ADP-ribose) polymerase (PARP) cleavage observed by the incubation with TNF-a/ActD. These different effects were not due to bcl-2 or mcl-1 levels. Inhibition of PGE2 synthesis by indomethacin increased the cell death induced by IL-1 beta/Act-D (59%). An inhibitor of caspase-8 significantly reduced only the TNF-alpha/ActD-incluced cell death (58%). Conclusion: TNF-alpha and IL-1 beta differentially regulate the apoptotic pathway in human chondrocytes. This difference is dependent on PGE2 and caspase-8 levels. (C) 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.